611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Sexually Transmitted Diseases
Resources
Basic InformationLatest News
HIV Testing, Treatment Not Reaching Many AmericansAn HIV Med Is Tied to Too-Small Heads in NewbornsAHA News: HIV Could Increase Risk of Death From Heart FailureStudies Confirm HPV Shot Is SafeNeedle Exchange Programs Guard Against HIVScientists ID Clue in Effort to Contain Herpes VirusHIV Could Speed Menopause Onset'Hey, What Is This?': Social Media, Not Docs, Increasingly Diagnosing STDsChlamydia Can Harm Male FertilitySTD Rates Continue to Rise in the U.S.Kidney Transplants Between People With HIV Are SuccessfulExperimental Genital Herpes Vaccine Shows Promise in MiceStudy Points to Herd Immunity Against HPV in Unvaccinated U.S. AdultsHaving HIV May Heighten Stroke RiskFor Kids Born With HIV, Taking Needed Meds Gets Harder With Age: StudyIs a Chlamydia Vaccine on the Horizon?Health Tip: Reducing Your Risk of HPVDual Therapy Might Be Advance Against Genital Herpes, Animal Study SuggestsHIV Lurking in Spinal Fluid Linked to Thinking ProblemsIn a First, Scientists Eliminate HIV From an Animal's GenomeMost Americans Have Never Had an HIV Test: CDCU.S. Expert Panel Supports HIV-Prevention Pill for People at High RiskHIV Patients More Likely to Have Heart Troubles, But Less Access to CareFor Women With HIV, Daily Life Can Impede Fight Against VirusSTDs: A Serious Health Threat at Every AgeHIV Meds Cut Transmission Risk to Zero, Even Without Condoms: StudyWeekly Infusion May Be Effective, Easier HIV TherapyDepression Plus HIV Can Turn DeadlyHow HIV Might Influence HPV Vaccination RatesSurgeons Perform First HIV-Positive Kidney Transplant From Living DonorCDC Cites Urgent Need to Expand HIV Testing, TreatmentHas America's Fight Against HIV Stalled?Meth Abuse Driving Big Spike in Syphilis CasesTrump's Goal of No New HIV Cases by 2030 Is Possible, Health Officials SayPresident Trump Unveils Plan to Stop U.S. HIV Transmissions by 2030
Questions and AnswersLinksBook Reviews
Related Topics

Homosexuality & Bisexuality

Is a Chlamydia Vaccine on the Horizon?

HealthDay News
by By Steven Reinberg
HealthDay Reporter
Updated: Aug 13th 2019

new article illustration

MONDAY, Aug. 12, 2019 (HealthDay News) -- A vaccine against the sexually transmitted disease chlamydia appears safe and potentially effective, an early trial suggests.

The phase 1 study included 35 healthy women. Those who were given injections of two possible vaccines developed antibodies to the chlamydia bacteria, but a lot more testing is needed before the vaccine would be ready for the public, the researchers added.

"An effective vaccine against chlamydia would have enormous public health and economic impact," said lead researcher Frank Follmann. He is director of infectious disease immunology at the Center for Vaccine Research at Statens Serum Institute in Copenhagen, Denmark.

"This is a promising first step on the road to develop a vaccine," he said. "The success of the HPV [human papillomavirus] vaccine has shown us how effective vaccination can be against a sexually transmitted infection. We hope to do the same with chlamydia and, in the long term, combine the two vaccines."

The results of this study are encouraging, and larger trials are planned, Follmann said. "The goal is to vaccinate girls [and potentially boys] before they become sexually active," he explained.

One expert said the findings show promise.

"Developing a vaccine against chlamydia has been challenging," said Fred Wyand, a spokesman for the American Sexual Health Association. "The study gives reason to be hopeful that vaccination to prevent chlamydia will someday be possible, but that goal lies in the future."

In the meantime, Wyand added, "it's important to keep in mind that chlamydia is easily diagnosed, treated and cured. This is why it's so important to test, and experts like the CDC recommend annual chlamydia testing for all sexually active women age 25 and under."

In the vaccine trial, the women were randomly assigned to one of two different vaccines or a placebo.

All of the women who received the vaccine produced antibodies to chlamydia, but one of the vaccines, called CTH522:CAF01, produced nearly six times more antibodies than the other vaccine, the investigators found.

That's the formula the researchers think should be pursued. From these results, however, it isn't a certainty that the vaccine will protect someone from chlamydia or if the protection will last over the long term, the researchers noted.

The most common side effect was reactions at the injection site, including pain and tenderness. These were mild and lasted only two to four days.

"Research shows that the combination of antibodies and T-cells can protect against chlamydia, but the vaccine needs to be tested in larger and more long-term clinical trials to see if it protects against infection in humans," Follmann said.

Chlamydia is the most common sexually transmitted infection in the world. It's caused by bacteria and infects 131 million people a year. It is mostly found in teens and young adults.

Because most cases don't have symptoms, the actual number of people infected might be much higher, the researchers said.

Both men and women can get the infection. Women get chlamydia in the cervix, rectum or throat. Men can get it inside the penis, rectum or throat. Chlamydia can be easily cured with antibiotics.

But one in six women who get the infection will suffer from pelvic inflammatory disease, which can cause chronic pelvic pain, infertility or ectopic pregnancy, where the egg is implanted outside the uterus, in the oviduct or fallopian tube.

Chlamydia is also associated with a likelihood of contracting other sexually transmitted infections, such as gonorrhea and HIV.

Women who are infected with chlamydia during pregnancy also have a higher risk for miscarriage, stillbirth and preterm birth.

The report was published online Aug. 12 in The Lancet Infectious Diseases.

Dr. Toni Darville is a professor of pediatrics, microbiology and immunology at the University of North Carolina at Chapel Hill. "Although clinical vaccine testing for chlamydia is in its infancy, this trial suggests optimism for the future," she said.

Questions that remain include whether the vaccine could protect women against upper reproductive tract damage, even if it can't prevent infection, she added.

"If the immune cells can kill the chlamydia infection before it reaches the oviducts or fallopian tubes, it could provide protection from the disease despite infection," said Darville, who co-wrote an accompanying editorial.

Darville also wonders if the vaccine were given to both men and women if it could protect women, who bear the brunt of the disease, from the infection.

More information

For more on chlamydia, head to the U.S. Centers for Disease Control and Prevention.